Literature DB >> 2684175

[The effect of Ginkgo biloba extract on neurophysiological and psychometric measurement results in patients with psychotic organic brain syndrome. A double-blind study against placebo].

B Hofferberth1.   

Abstract

The range of typical symptoms of cerebro-organic syndrome such as dizziness, memory and concentration loss, and orientation disorders can either be measured objectively within a clinical trial or can be observed subjectively. Thirty-six patients with classical symptoms of organic syndrome were recruited into a placebo-controlled double-blind trial in which the therapeutic effect of Ginkgo biloba extract EGb 761 (rökan) was measured by the following objective criteria: quantified EEG, saccadic eye movements and psychometric tests (Wiener Determination Test, Number Connection Test). Following 2 weeks' wash-out, 40 mg. EGb 761 was administered 3 times daily (= 120 mg daily dose) for 8 weeks. The control group received placebo capsules of identical external appearance. The tests listed above were carried out prior to treatment and after 4 and 8 weeks' therapy with the exception of quantitative EEG which was recorded at the beginning and end of treatment only. Patients presenting with pathological findings for at least two of the four test criteria were admitted to the trial. Patients receiving unpermitted supplementary medication or suffering from acute cardiovascular disturbances or digestive and metabolic disorders were excluded from the trial. A highly significant difference could already been seen after 4 weeks of therapy and also after 8 weeks in the results of both the saccadic test and the psychometric tests compared to the placebo control group. Saccade duration was shortened and the latency reduced. In parallel, the number of correct answers given in the Wiener Determination Test and Number Connection Test increased significantly compared to the control group. (ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2684175

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  10 in total

Review 1.  Complementary and alternative medicines in the treatment of dementia: an evidence-based review.

Authors:  Bruce Diamond; Susan Johnson; Kathleen Torsney; Jennifer Morodan; Brian Prokop; Dana Davidek; Patricia Kramer
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

2.  Dietary rescue of fumble--a Drosophila model for pantothenate-kinase-associated neurodegeneration.

Authors:  Y Yang; Z Wu; Y M Kuo; B Zhou
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

Review 3.  Botanical and dietary supplements for menopausal symptoms: what works, what does not.

Authors:  Stacie E Geller; Laura Studee
Journal:  J Womens Health (Larchmt)       Date:  2005-09       Impact factor: 2.681

4.  Interventions for preventing delirium in older people in institutional long-term care.

Authors:  Rebecca Woodhouse; Jennifer K Burton; Namrata Rana; Yan Ling Pang; Jennie E Lister; Najma Siddiqi
Journal:  Cochrane Database Syst Rev       Date:  2019-04-23

Review 5.  Ginkgo biloba for cerebral insufficiency.

Authors:  J Kleijnen; P Knipschild
Journal:  Br J Clin Pharmacol       Date:  1992-10       Impact factor: 4.335

Review 6.  [External validity of clinical trials for treatment of dementia with ginkgo biloba extracts].

Authors:  G Bornhöft; S Maxion-Bergemann; P F Matthiessen
Journal:  Z Gerontol Geriatr       Date:  2008-03-11       Impact factor: 1.281

7.  Therapeutic approaches to age-associated neurocognitive disorders.

Authors:  R O'Hara; C Derouesné; K N Fountoulakis; J A Yesavage
Journal:  Dialogues Clin Neurosci       Date:  2001-09       Impact factor: 5.986

8.  Comparative Electropharmacological Actions of Some Constituents from Ginkgo biloba Extract in Guinea-pig Ventricular Cardiomyocytes.

Authors:  Hiroyasu Satoh
Journal:  Evid Based Complement Alternat Med       Date:  2004-10-27       Impact factor: 2.629

9.  A retrospective classification of diagnoses in terms of DSM-5 for patients included in randomized controlled trials of Ginkgo biloba extract EGb 761(®).

Authors:  Robert Hoerr; Michael Zaudig
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-08-13       Impact factor: 5.270

10.  Efficacy and safety of Ginkgo biloba standardized extract in the treatment of vascular cognitive impairment: a randomized, double-blind, placebo-controlled clinical trial.

Authors:  Vida Demarin; Vanja Bašić Kes; Zlatko Trkanjec; Mislav Budišić; Marija Bošnjak Pašić; Petra Črnac; Hrvoje Budinčević
Journal:  Neuropsychiatr Dis Treat       Date:  2017-02-16       Impact factor: 2.570

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.